Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677300 | 1.00 | XDH (0.41) | XDHKDM4ECSNK2A1SMN1; SMN2TMIGD3 | |
| SCHEMBL130696 | 0.81 | XDH (0.57) | XDHYTHDC1 | |
| SCHEMBL30115173 | 0.81 | CDK1 (0.41) | XDHKDM4ECSNK2A1SMN1; SMN2 | |
| SCHEMBL29745 | 0.81 | CDK1 (0.41) | XDHKDM4ECSNK2A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28873719 | 0.79 | CDK1 (0.40) | XDHKDM4ECSNK2A1SMN1; SMN2 | |
| SCHEMBL1358951 | 0.79 | CDK1 (0.40) | XDHKDM4ECSNK2A1SMN1; SMN2 | |
| SCHEMBL7521321 | 0.79 | CDK1 (0.40) | XDHKDM4ECSNK2A1SMN1; SMN2 | |
| SCHEMBL8485064 | 0.79 | PDPK1 (0.36) | — | |
| SCHEMBL14224143 | 0.78 | XDH (0.40) | XDHCSNK2A1 | |
| SCHEMBL14196060 | 0.78 | XDH (0.36) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| US-7399754-B2 | N2-quinoline or isoquinoline substituted purine derivatives | ZHEJIANG MEDICINE CO., LTD. (CN) | 2008-07-15 | — | — | US | disclosed |
| US-5990118-A | NOVEL PURINE COMPOUNDS AND TRIAZOLOPURINE COMPOUNDS WHICH INHIBIT XANTHINE OXIDASE; REMEDIES FOR HYPERURICEMIA, AND AS PREVENTIVE AND THERAPEUTIC AGENTS FOR GOUT | YAMASA CORPORATION (JP) | 1999-11-23 | — | — | US | disclosed |
| EP-0811624-A1 | PURINE COMPOUNDS AND XANTHINE OXIDASE INHIBITORS | YAMASA CORPORATION (JP) | 1997-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | XDH 2221/4885KDM4E 2168/4885CSNK2A1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.